Bajaj Healthcare’s Vadodara Unit Gets Australian Approval, Stock Hits High

Bajaj Healthcare’s Vadodara facility earned approval from Australia’s Therapeutic Goods Administration (TGA), boosting its stock to a 52-week high. This recognition allows the company to supply APIs directly to Australia and New Zealand, alongside its existing approvals from the US and EU. With strong profits and growing global presence, Bajaj expects increased CDMO contracts from this achievement, underlining its role in pharmaceutical innovation.